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Background. Metastatic extraorbital  sebaceous carcinoma is a rare event that could involve the head and neck. 
The treatment of choice for the initial stage of the disease is surgery and/or radiotherapy. The treatment of recurrent 
or advanced disease is still controversial.
Material and methods. Extensive literature search was done, and the treatment options are discussed. 
Results. Results. The literature search found several treatment modalities in use for the treatment of metastatic ex-
traorbital  sebaceous carcinoma. Electrochemotherapy was not included in the reported treatments. We used this 
technique for a man of 85 years old with a recurrent and locally metastatic extraorbital sebaceous carcinoma of 
the scalp.During the period of 8 months, two sessions of electrochemotherapy were employed, which resulted in an 
objective response of the tumour and good quality of life. 
Conclusions.  Electrochemotherapy has shown to be a interesting tools for treatment of  metastatic extraorbital 
sebaceous carcinoma  when other radical options are not available or convenient.
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Introduction
The sebaceous carcinoma (SC) is a rare and poten-
tially aggressive adnexial neoplasm of sebaceous 
gland. Its prevalence varies from 0.05% to 0.7% of 
all the skin cancers.1 Approximately, the 25% of 
sebaceous carcinomas occur in extra-orbital sites, 
in 15% of these cases the torso and in 10% the ex-
tremities are affected.2
Extraorbital SC is considered as a less aggres-
sive neoplasm when compared with its periorbital 
counterpart (a reduced tendency for regional me-
tastasis, 1.4% for extraorbital vs. 4.4% for periorbi-
tal).3 Despite this, highly aggressive extraorbital SC 
has been reported in the literature.4 
The typical clinical presentation is indistin-
guishable from other more common dermatologic 
conditions. Usually, clinical features are a painless 
pink or yellow firm papule, gradually enlarging 
and ranging from skin-coloured to red papules, 
plaques, or nodules. This aspecific presentation 
delays the time of diagnosis. Histologically an 
unencapsulated, lobular, dermally based collec-
tions of sebaceous and undifferentiated cells that 
may contain lipid granules in the cytoplasm with a 
characteristic “frothy” appearance.5
SC requires vigilant follow-up after treatment 
due to its potentially aggressive nature. Local re-
currence rate is 4%–28% for both periorbital and 
extraorbital lesions.6
Radiology and Oncology  |  Ljubljana  |  Slovenia  |  www.radioloncol.com
Radiol Oncol 2016; 50(3): 308-312.
Ribero S et al. / Electrochemotherapy for sebaceous cell carcinoma 309
Pathogenesis of SC is poorly understood, how-
ever associations with Muir-Torre syndrome7 is 
described as well as irradiation8, immunosuppres-
sion9, familial retinoblastoma.10 This neoplasm can 
occur on any sebaceous glands rich skin, particu-
larly face, scalp, and neck. For unknown reasons 
SC is more prevalent in periorbital skin (39%), es-
pecially eyelid, and in extraorbital skin of the head 
and neck (41%). Some genitalis and extremities 
cases are reported.11
The management of skin cancer of the head and 
neck region is still challenging. Surgery is com-
monly considered the treatment of choice and 
significantly improves the locoregional control, 
if associated with adjuvant radiotherapy.12 In the 
head and neck area, where it is difficult to obtain 
safety margins wide enough, radiotherapy can be 
the first treatment option. In particular some ar-
eas have been included in the last American Joint 
Committee on Cancer (AJCC) classification as 
more at risk of involved margins after surgery in 
squamous cell carcinoma.13
Methods
A systematic literature review for case reports of 
extra-ocular, cutaneous, multifocal metastasizing 
SC in the time between 1960 and 2015 was con-
ducted. We therefore searched the literature for all 
cases mentioning a skin directed therapy and re-
sponse results for metastatic sebaceous carcinoma 
utilizing PubMed’s MEDLINE database. 
Results
Local and distant cutaneous/subcutaneous metas-
tases were described in the course of disease in 8 
cases (Table 1).14-21 Heterogeneity regarding man-
aging of skin cutaneous metastases in head and 
neck is due to the variability in size, site and clini-
cal comorbidities. Although a few reported cases 
have shown that skin directed therapy regimens 
help in palliative treatment, prospective studies 
have not been performed and their role has not yet 
been settled due to the rarity of this disease.
FIGURE 1 . Metastatic sebaceous carcinoma, before electrochemotherapy.
TABLE 1. Clinical cases of extra-ocular metastatic sebaceous carcinoma treated with skin directed therapies
Authors Sex Age Localization / metastases Treatment Prognosis
Mellette et al. (1981) 14 M 63 Nose / cutaneous and paratiroid metastases
Curettage and surgical excision
Parotidectomy
Radiotherapy
nod
Moreno et al. (2001) 16 M 45 Left axilla / lymph node metastases Surgery 6 months
Moura et al. (2002) 17 M 71 Forehead / cutaneous, nodal and skeletal metastases
Surgery
Local radiation
Chemo and cryosurgery
4 years without 
recurrence
Khan et al. (2003) 18 F 49 Vulva / subcutaneous and nodal metastases
Surgery
Radiotherapy
Palliative chemotherapy
nod
Murphy et al. (2004) 19 M 71 Right nostril / left nostril metastases Surgery 18 months without recurrence
Swick et al. (2009) 20 M 83 Right flank / subcutaneous, nodal, pulmonary and hepatic metastases Palliative radiotherapy nod
Bhat et al. (2011) 21 M 32 Left feet / cutaneous metastases SurgeryChemotherapy nod
Bolm et al. (2015) 15 M 87 Left ear /  nodal, pulmonary and cutaneous metastases Surgery 
18 months without 
recurrence
Our case M 85 Scalp / cutaneous and subcutaneous metastases Electrochemotherapy 2 months 
A B
C D
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Electrochemotherapy for sebaceous 
carcinoma
Herein we report a case of a 85-years old Caucasian 
male came to our attention for the first time pre-
senting 9 papulo-nodular lesions on the scalp 
ranging from 1 to 3 cm in diameter (Figure 1 A–B). 
Moreover, some of them bled frequently. The clini-
cal scenario was suggestive for locally metastatic 
cutaneous carcinoma but the eruptive emergence of 
skin lesions necessitated a better diagnostic deter-
mination. One year before, he had a prior surgical 
excision of a nodular lesion of the scalp carried out 
in another hospital treated with skin grafting and 
histologically diagnosed as cutaneous carcinoma. 
Thus, we performed three skin biopsies  on three 
different lesions with histopathological diagnosis 
of SC. The total body PET-CT scan confirmed the 
lack of visceral metastatic spreading.
A month after the first visit we observed the ap-
pearance of new lesions on the scalp and those pre-
viously described were increased in size. After col-
lecting the informed consent for the off label pro-
cedure, we performed electrochemotherapy with a 
30% reduced dose of the 15000 IU/m2 intravenous 
bleomycin due to the patient impaired renal func-
tion using the Cliniporator TM device (IGEA Ltd, 
Carpi, Italy). The treatment of tumour area of 
20 cm2 was performed with hexagonal electrodes 
in 80 runs of electric pulse applications. 
Neither post-treatment complications, nor cra-
nial nerves injuries nor post-procedural pain were 
observed. Globally 16 lesions were treated with a 
complete bleeding control.
After one month the lesions treated were flat 
(Figure 1). Despite this other 4 new lesions ap-
peared in the area on the previous skin graft. A sec-
ond section of ECT was performed with the same 
parameters. 
Two months after the second electrochemo-
therapy session the patients has not showed any 
relapse and was disease free (Figure 2). 
Discussion
Herein we described the first case of Electro-
chemotherapy in the treatment  of metastatic  ex-
traorbital SC. SC typically consists of roundish 
nests of tumour-cells with central necrosis, in prox-
imity to normal sebaceous glands. The tumour 
cells of not well-differentiated SC may display 
high- grade features with a high frequency of mi-
totic figures. Angiolymphatic invasion is a consist-
ent finding in SC, like an intraepidermal pagetoid 
tumour-spread.
The role of Immunohistochemistry in the di-
agnosis of SC is fundamental as it consistently 
expresses Epithelial Membrane Antigen (EMA) 
(which is absent in squamous cell carcinoma and 
basal cell carcinoma) and, in the centres of the tu-
mour-nests, CD15. Surrounding sebaceous glands 
are used as a positive internal control for CD15. CD 
10 is usually absent in SC. Ansai et al.22 showed that 
positivity for adipophilin is most useful in the di-
agnosis of sebaceous neoplasms.
Because of the rarity of this tumour, no standard 
therapy exists specially in its metastatic onset. In 
the last years, electrochemotherapy has been pro-
posed as a novel therapeutic option for the control 
of recurrent cutaneous, subcutaneous or mucosal 
neoplastic lesions of different histologies.23-24 There 
is an increasing body of published clinical data on 
electrochemotherapy.25 This procedure achieves 
rates of objective response between the 56% and 
the 100%, depending on the tumour size and his-
tology.26-27 Electrochemotherapy combines the ad-
ministration of a poorly permeant cytotoxic agent, 
such as bleomycin with the local application of 
electric pulses that induce reversible electropora-
tion, thus improving drug diffusion into cells.28 
Electrochemotherapy has demonstrated a high 
rate of efficacy and favorable toxicity profile in a 
European multicenter study on skin metastases 
from different tumour histotypes.29 In this study, 
the objective response (OR) rate on treated tumour 
FIGURE 2. Response to treatment after two electrochemotherapy sessions (2 months).
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nodules was 89.0% with complete regression in 
73.3% of cases. A recently published meta-analysis 
including 47 prospective studies comparing five 
skin-directed therapies (electrochemotherapy, 
radiation, photodynamic therapy, intralesional 
therapy, and topical therapy), electrochemother-
apy demonstrated an OR rate of 75.4% (complete 
response [CR] rate 47.5%) with a low toxicity pro-
file (grade 3 in less than 6% of patients).30 The main 
advantages of electrochemotherapy include: 
• high success rate in local tumour control after a 
single session; 
• no damage to healthy peripheral tissue (using 
low doses of chemotherapeutic agents electro-
chemotherapy is very specific for dividing tu-
mour cells, sparing the surrounding normal tis-
sue); 
• no protein denaturation, so that tumour an-
tigens are not destroyed and may elicit an im-
mune response; 
• excellent safety profile (in clinical use, no seri-
ous adverse events were reported in association 
with electrochemotherapy; 
• advantageous cost/benefit ratio: the technology 
and the drugs used, in particular bleomycin, do 
not require large investments; 
• improvement of patient’s quality of life.
Reported studies showed clinical activity, posi-
tive impact on patients subjective clinical per-
ception and low toxicity profile of electrochemo-
therapy and encourages us to propose to patients 
this technique with an palliative intent, after the 
failure of conventional treatment options, such as 
surgery, radiotherapy, and systemic therapies.31 
Especially in Kaposi Sarcoma, where skin lesions 
often cause pain and disfigurement and may lead 
to functional disability, electrochemotherapy has 
become the standard of care as first line treatment 
strategy.32 
To the best of our knowledge no data on skin 
metastases from extracutaneous SC treated with 
electrochemotherapy are documented in the litera-
ture. Extraorbital SC has a high risk of local recur-
rence and it usually appears in elderly. Herein, we 
reported a CR at 2 months time from two sessions 
of electrochemotherapy for SC skin metastases. T he 
choice of using electrochemotherapy in our patient 
was determined by the locally advanced pathol-
ogy that would not permit a surgical resection and 
by the patient’s refusal of radiotherapy. This case 
demonstrates that electrochemotherapy can be 
considered as an effective palliative treatment op-
tion for patients with recurrent or advanced-stage 
tumour, not suitable for conventional treatments.
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